Vascular cartilaginous metaplasia and calcification are common in patients with atherosclerosis. However, sources of cells contributing to the development of this complication are currently unknown. In this study, we ascertained the origin of cells that give rise to cartilaginous and bony elements in atherosclerotic vessels.
Introduction
Vascular calcification (VC), a complication arising from calciumphosphate salt deposition in the form of hydroxyapatite in vasculature, is commonly associated with ageing and is highly prevalent in patients with atherosclerosis, type II diabetes mellitus (T2D), and endstage renal disease (ESRD). 1 -3 Clinical consequences of VC are largely dependent upon its location, extent, and organs affected. In atherosclerosis, calcification is found mainly in the intima of blood vessels, in the form of dispersed, punctate nanocrystals. As lesion development proceeds, these calcium-phosphate crystals aggregate to produce larger crystals associated with the necrotic core of atheromas. The presence and extent of intimal calcification has been reported to be highly correlated with atherosclerotic plaque burden in addition to the risk of myocardial infarction, plaque instability, and stroke. 1 The notion that VC contributes to the susceptibility of plaque rupture was recently confirmed in an elegant study by Ehara et al. 4 that spotty calcification typified the culprit plaques in patients with acute myocardial infarction. VC also occurs in the media of blood vessels with or without association to atherosclerosis. 3, 5 Calcium-phosphate salt typically deposits circumferentially along the elastic lamina of arterial media, 5 leading to increased arterial stiffness and pulse wave velocity and pressure that impairs cardiovascular function. 6 In T2D and ESRD patients, arterial medial calcification is highly prevalent and considered a major contributor to the heightened risk of cardiovascular mortality, stroke, and lower-limb amputation observed in this population. 2, 3, 6 Despite the associated risk factors for cardiovascular disease, there are no drug therapies currently available to treat or prevent VC. To advance the development of targeted therapeutics, it is important to understand mechanisms underlying this pathology, especially what cell types give rise to osteochondrogenic precursor-, osteoblast-, and chondrocyte-like cells in calcifying vasculature and whether this is a common phenomenon among various disease conditions. A growing number of mechanistic studies have highlighted VC as an actively regulated process, potentially involving osteochondrogenic differentiation of vascular wall cells in response to disease-specific environmental cues. 5,7 -10 Molecules that initiate and regulate osteoblastic and chondrocytic differentiation, e.g. Runx2/Cbfa1, BMP2, Msx2, osterix, and Sox9, were frequently observed in the early stages of VC. 7, 9 Cells with osteoblastic and/or chondrocytic properties, as indicated by expression of bone and/or cartilage marker proteins, e.g. alkaline phosphatase, bone Gla protein, type II collagen (Col II), and osteopontin, 5, 9 were often co-localized with calciumphosphate deposits within the vessel wall. In fact, outright ossification was observed in 10 -25% of calcified atherosclerotic arteries, as evidenced by bone marrow (BM), cartilage, and mature lamellar bone. 5, 11 More importantly, osteochondrogenic differentiation and matrix calcification were reproduced in vitro using cells isolated from normal vasculature, such as calcifying vascular cells cloned from aortic media 8 and uncloned heterogeneous vascular smooth muscle cells (SMCs).
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The most direct evidence supporting a critical role of mural cells in VC is from the study of matrix Gla protein knockout (MGP2/2) mice. These mice develop VC arterial medial calcification early in life with features similar to Monckeberg's medial sclerosis observed in T2D and ESRD patients. 5, 10 Using a Cre-loxP site-specific recombination technique that allows genetic fate mapping of specific cell types in vivo, 12,13 vascular SMCs were found to contribute to essentially all of the chondrocyte-like cells ( 97%) in calcifying MGP2/2 vessels, as evidenced by the loss of SMC lineage markers (SM-MHC, SM22a, and SMa-actin) coupled with the gain of osteochondrogenic markers (Runx2/Cbfa1, osteopontin, and Col II) within cells of b-galactosidase activity (cells that had once exhibited SMC property). In these mice, circulating progenitors did not contribute to osteochondrogenic precursor-or chondrocyte-like cells. The MGP2/2 genetic fate mapping study provided significant insight into the role of SMCs in a medial calcification model resembling human autosomal recessive genetic disorder, Keutel syndrome, 14 and long-term warfarin treatment. 15 Numerous studies suggest that intimal calcification in atherosclerotic vessels differs from medial calcification of Monckeberg's medial sclerosis by its prevalent diseases, pathogenesis, histoanatomic locations, and possibly histological appearance. 2 -5,7,16 Additionally, potential cell sources for osteogenic lineages in atherosclerotic lesions include not only vascular SMCs, but also local and circulating multipotent progenitor cells, 7, 8, 17 although there has been no genetic fate mapping study that directly tested these possibilities. In the present study, we applied the Cre-loxP site-specific recombination system to genetically label cells of SM origin in low-density lipoprotein receptor mutant (LDLr2/2) mice and apolipoprotein mutant (ApoE2/2) mice, providing a direct test of whether SMCs undergo lineage reprogramming and contribute to the development of cartilaginous metaplasia and calcification in atherosclerotic vessels. We also employed a BM transplantation (BMT) technique to trace cells derived from circulation in ApoE2/2 mice, 18 allowing us to determine the contribution of BM-derived cells. Our studies are the first to provide definitive evidence of cell sources that play an important role in the osteochondrogenic processes observed in atherosclerotic vessels.
Methods

Genetic fate mapping of LDLr mutant and ApoE mutant mice
Cells of SM origin were marked by SM22a-Cre and R26R transgenes. Briefly, LDLr2/2 mice (002207) and ApoE2/2 mice (002052) were purchased from the Jackson Laboratory and bred to SM22a-Cre (gift from Dr Herz, UT) and R26R (gift from Dr Soriano, FHCRC) transgenic alleles to produce SM22a-Cre+/0:R26R+/0:LDLr2/2 and SM22a-Cre+/0:R26R+/0:ApoE2/2 mice, respectively, for the study.
Ten-week-old SM22a-Cre+/0:R26R+/0:LDLr2/2 mice were fed with a high-fat, high-cholesterol diet (HFD; Research Diets Inc., 1.25% cholesterol, 39.9% kcal fat, 40% kcal carbohydrate) to induce atherosclerosis and VC. Normal chow was used as a diet control. SM22a-Cre0/0:R26R+/ 0:LDLr2/2 mice were used as controls to determine specificity and efficiency of Cre recombination. SM22a-Cre+/0:R26R+/0:LDLr2/2 mice were anaesthetized with 50 -180 mg/kg pentobarbital intraperitoneally followed by exsanguination via cardiac puncture for blood collection at 18 -30 weeks on diet. SM22a-Cre+/0:R26R+/0:ApoE2/2 mice were fed with normal chow and sacrificed by pentobarbital injection (300 mg/ kg) at 45 -60 weeks of age. Fasted sera were collected for blood chemical analyses; aortic arches and innominate arteries were collected for histology. A total of 64 LDLr2/2 mice and 12 ApoE2/2 mice were examined.
Marrow transplantation to generate
ApoE2/2:GFP1/0 chimeric mice Male ApoE2/2:GFP+/0 mice of 8 -9 weeks old were sacrificed by Nembutal injection on the day of transplantation and marrow cells were harvested from femurs. The cells were pelleted and re-suspended with sterile phosphate-buffered saline (PBS) to a final concentration of 4 × 10 7 cells/ mL. Recipient ApoE2/2 mice received neomycin water (2 mg/mL) 1 week prior to BMT and 2 weeks thereafter and were lethally irradiated by 9.5 Gy (Cesium-137 g-ray source) 24 h prior to BMT. On the day of BMT, each recipient mice was anaesthetized with isoflurane inhalation (3 -5% for induction and 1 -3% for maintenance) and transplanted with 1.2 × 10 7 ApoE2/2:GFP+/0 marrow cells via retro-orbital sinus injection. ApoE2/2:GFP+/0 chimeric mice were maintained in a specific pathogen-free environment, fed with normal chow, and euthanized for study by pentobarbital injection (300 mg/kg) 10 weeks after BMT. Engraftment rate was assessed by flow cytometric analysis of peripheral blood collected from the chimeric ApoE2/2 mice. Briefly, whole blood was lysed with erythrocyte lysis buffer (15.5 mM NH 4 Cl, 1.0 mM KHCO 3 , 0.1 mM EDTA). Nucleated cells were collected and re-suspended in ice-cold PBS containing 2% foetal bovine serum and 5 U/mL heparin. The cells were stained with propidium iodide and analysed by flow cytometry for GFP-positive cells. More than 83 + 5% of peripheral blood cells in the ApoE2/2:GFP+/0 chimeric mice were of donor origin. 18 Animals were maintained in a specific pathogen-free environment and genotypes were determined as described. 19 All protocols are in compliance with the NIH Guideline for the Care and Use of Laboratory V. Naik et al.
Animals and were approved by the Institutional Animal Care and Use Committee, University of Washington.
X-gal staining
Tissues dissected from SM22a-Cre+/0:R26R-LacZ+/0:LDLr2/2, SM22a-Cre0/0:R26R-LacZ+/0:LDLr2/2, SM22a-Cre+/0:R26R-LacZ+/ 0:ApoE2/2, and SM22-Cre0/0:R26R+/0:ApoE2/2 mice were stained using a b-galactosidase stain kit (Special Media) as described previously. 19 Specifically, tissues were fixed on ice with tissue fixative (catalog # BG-5-C) for 1.5 h, followed by a 30-min wash in tissue rinse solution A (catalog # BG-6-B) at room temperature and a 5 min wash in tissue rinse solution B (catalog # BG-7-B). The tissues were then stained with freshly prepared b-gal tissue stain solution (catalog # BG-8-C and BG-3-G) at 378C for 2 -4 h depending on the tissue type and size.
Tissue preparation and histochemical and immunohistochemical staining
X-gal-stained tissues were post-fixed with Methyl Carnoy's fixative prior to processing and embedding in paraffin. Tissues dissected from ApoE2/2:GFP+/0 chimeras were fixed with 10% buffered formalin and embedded in paraffin. Five-micrometre sections were used for histochemical and immunohistochemical analyses. Movat Pentachrome stain was used to visualize morphology, von Kossa stain was used to detect calcium-phosphate minerals, antibodies recognizing SM22a (ab10135, Abcam; 0.25 mg/mL), MOMA-2 (YSRTMCA519G, Accurate Chemical & Scientific Corporation; 10 mg/mL), Runx2/Cbfa1 (MAB2006, R&D Systems; 5.0 mg/mL), Sox-9 (sc-20095, Santa Cruz; 3.0 mg/mL), type II collagen (AB761, Millipore; 50 mg/mL), and green fluorescence protein (A11122, Invitrogen; 3.3 mg/mL) were used to detect SMCs, macrophages, osteochondrogenic precursors, chondrocytes, and cells carrying GFP transgenes. All immunohistochemical staining were validated with nonspecific IgG controls as well as negative and positive control tissues, e.g. aortic sections from LDLr2/2 mice fed with normal chow as negative controls and femur sections as positive controls for osteochondrogenic and chondrocytic marker proteins. Sections were counterstained with either methyl green or nuclear fast red (Vector) as indicated in the figure legends.
To quantify osteochondrogenic precursors that were derived from vascular SMCs or BM cells, triple-stained aortic sections (b-galactosidase or GFP, Runx2/Cbfa1, and nuclear fast red) were used. In each group, slides from seven randomly selected animals were imaged. Total cell numbers, cells positive for Runx2/Cbfa1, and cells positive for both Runx2/Cbfa1-and b-galactosidase (or GFP) in the entire cartilaginous and calcifying intimal lesions were counted. Cell numbers were normalized to the lesion areas. The percentage of Runx2/Cbfa1-positive cells in cartilaginous metaplasia and calcification lesions was used to evaluate osteochondrogenic differentiation. The percentage of Runx2/Cbfa1-positive cells with b-galactosidase activity (stained blue by X-gal) is noted as SM-derived osteochondrogenic cells. The percentage of Runx2/Cbfa1-positive cells that were also positive for GFP is noted as BM-derived osteochondrogenic cells. A similar approach was employed to quantify chondrocyte-like cells that were derived from vascular SMCs using triple-stained sections for X-gal, type II collagen, and nuclear fast red.
Statistical analysis
Data, shown as means + SD, were analysed with Student's t-test or ANOVA to determine the significance of differences. Data were considered to be statistically significant at a P-value of ,0.05.
Results
LDLr2/2 mice fed with HFD developed cartilaginous metaplasia and calcification in atherosclerotic intima and arterial media
To determine what cell types contribute to the development of VC associated with atherosclerosis, we genetically marked cells of SM origin in LDLr2/2 mice (see Supplementary material online, Figure S1A -D). 19 The mice were fed with HFD to induce atherosclerosis and VC and were terminated at 18 -30 weeks on diet. As seen in Table 1 , mice fed with HFD showed an increase in serum cholesterol and triglyceride levels at all time points (P ≤ 0.001-0.05) compared with the normal chow counterparts. The HFD group gained more body weight, statistically significant only at 18-week diet-fed (32 + 5 vs. 22 + 3 g), while their fasted glucose levels were similar to mice fed with normal chow, suggesting that these mice were not diabetic. In addition, no renal failure and related hyperparathyroidism were found in these animals as determined by their serum blood urea nitrogen, phosphorus, and alkaline phosphatase levels. In arteries of LDLr2/2 mice fed with HFD, cartilaginous matrices consisting of a collagen-(yellow) and proteoglycan- (blue) extracellular matrix embedded with chondrocyte-like cells characterized by relatively large amount of clear cytoplasm surrounded by a lacunar rim (arrowheads) were first found in deep intima and inner medial layers of the vessels ( Figure 1A and B) . Interestingly, cartilaginous metaplasia tended to occur adjacent to areas of elastic lamina breakage (arrows), outside the lipid core, and independent from areas containing macrophage foam cells. Cartilaginous metaplasia could be found in the absence of outright calcification and was observed as early as 18 -20 weeks. Around 33% of LDLr2/2 vessels displayed chondrocyte-like cells ( Table 2) , with only one out of 18 (5%) calcified at this stage ( Figure 1C, dark brown) . By 24 weeks, the animals showed rapid progression of vascular osteochondrogenesis, with large areas filled with chondrocyte-like cells ( Figure 1D and E, arrowheads) in all vessels examined (13/13). Approximately 46% were calcified, mostly in the deep intima and inner medial layers adjacent to the lesions ( Figure 1F , brown and arrows, and Table 2 ). By 30 weeks, all the animals (13/13) had lesions containing both cartilaginous metaplasia and calcification ( Table 2) . These results suggest that the development of cartilaginous metaplasia may have preceded calcification in LDLr2/2 vessels, similar to the process of endochondral ossification in hard tissue. Finally, mice fed with normal chow did not develop atherosclerosis, cartilaginous metaplasia, or calcification in their vasculature ( Table 2 ) and were negative for markers of osteochondrogenesis (Runx2/Cbfa1) and chondrocytes (Sox9 and Col II) (data not shown).
3.2 Cells of SM origin are the major source of osteochondrogenic precursors and chondrocytes seen in LDLr2/2 vessels
To determine whether SMCs contribute to vascular osteochondrogenic differentiation, SM22a-Cre+/0:R26R+/0:LDLr2/2 vessels were stained with X-gal to identify cells of SM origin. As shown in Figures 1C and F, and 2 , cells in cartilaginous metaplasia and calcified regions were primarily stained blue by X-gal, indicating that they had once acquired SMC characteristics. However, these cells no longer expressed SMC lineage proteins, e.g. SM22a ( Figure 2B and F, lack of brown stain). Instead, they developed osteochondrogenic and chondrocytic properties as identified by transcriptional factors Runx2/Cbfa1 ( Figure 2C ) and Sox9 ( Figure 2G) , and chondrocyte marker protein, Col II ( Figure 2D and H ). Because these cells were also stained blue by X-gal, they were likely to have differentiated from vascular SMCs, either migrating from arterial media or from circulating multipotent cells that had expressed SM22a at an earlier time point. Since LDLr2/2 mice fed with HFD also developed lipid-filled lesions, we stained these sections for macrophages with MOMA-2 antibody. As shown in Figure 3 , MOMA-2-positive cells were mostly found in the lipid-laden areas (Figure 3A , brown; Figure 3D and F, green fluorescence) and were neither stained by X-gal ( Figure 3A , lack of blue in brown area) nor co-localized with chondrocyte marker, Sox9 ( Figure 3E and F, red fluorescence). Runx2/Cbfa1 is a critical transcription factor that governs early osteochondrogenic differentiation and chondrocyte maturation in skeletal tissue. 20 To better understand osteochondrogenic differentiation of cells in atherosclerotic vessels, we analysed the expression patterns of Runx2/Cbfa1 at multiple stages of vascular cartilaginous metaplasia and calcification. Interestingly, Runx2/Cbfa1 appeared in LDLr2/2 vessels as early as 18 weeks, accounting for 40.9% of cells inside the intimal lesions (Figure 4A) . Most of the Runx2/Cbfa1-positive cells were found in the intimal areas of cartilaginous metaplasia, notably areas containing early chondrocytic cells and cartilaginous matrix ( Figure 4C , brown, vs. Figure 1D , arrowheads and yellow), as well as in areas in which cells were organized in a pattern similar to that found in proliferating zones of growth plates ( Figure 4D, asterisks) . Some Runx2/Cbfa1-positive cells were found in media adjacent to cartilaginous lesions (arrows) and in intima towards the lumen (arrowheads). Few were also seen in the adventitia ( Figures 2C and 4D and E, brown nuclear stain). The expression of Runx2/Cbfa1 peaked at 24 weeks and decreased thereafter ( Figure 3A) . At later time points, Runx2/Cbfa1 was found in cells with morphologies resembling hypertrophic chondrocytes, with and without calcification ( Figures 2C and 4D) . Most of the Runx2/ Cbfa1-positive cells were stained blue by X-gal, consistent with the theory of SMCs undergoing lineage reprogramming towards osteochondrogenesis. In addition, cells residing in the intima adjacent to the lumen were not stained by X-gal, identifying their non-SMC source ( Figures 2C and 4D and E; arrowheads). Contribution of SMCs to osteochondrogenic precursors was further quantified using X-gal, Runx2/Cbfa1 antibody, and nuclear fast red triple-stained sections. Of 1000-2000 Runx2/Cbfa1-positive cells from lesion areas of seven randomized animals examined at each time point, 75 -88% was stained blue by X-gal ( Figure 4B) , supporting the notion that vascular SMCs are the major source of osteochondrogenic precursors observed in cartilaginous metaplasia and calcification lesions of LDLr2/2 vessels. Finally, we quantified the proportion of chondrocyte-like cells that were derived from SMCs using X-gal, Col II antibody, and nuclear fast red triple-stained sections. Of 2720 Col II-positive cells from sections of 14 randomly chosen animals at 24-to 30-week diet-fed, 2664 cells were stained blue by X-gal (98%; see Supplementary material online, Figure S2A ), suggesting that chondrocytic cells found in LDLr2/2 vessels were either originally derived from SMCs or gained partial SMC feature, such as SM22a expression, on their way to differentiating into chondrocytes.
SMCs also give rise to osteochondrogenic precursors and chondrocytes in atherosclerotic ApoE2/2 vessels
To confirm our findings in atherosclerotic LDLr2/2 mice, we employed the same genetic fate mapping strategy to ApoE2/2 mice, a different atherosclerotic mouse model, to determine whether SMCs play a similar role in vascular cartilaginous metaplasia and calcification. As shown in Figure 5 , ApoE2/2 mice developed not only atherosclerosis but also cartilaginous metaplasia and calcification at 45 -60 weeks of age. Similar to atherosclerotic LDLr2/2 vessels, cells once exhibited SMC features (stained blue by X-gal) in cartilaginous metaplasia and calcification areas ceased to express SMC lineage proteins ( Figure 5B and F ) , and instead, gained osteochondrogenic ( Figure 5C ) and chondrocytic ( Figure 5G and H ) properties. Approximately 76 -83% Runx2/Cbfa1-positive cells had b-galactosidase activity in atherosclerotic lesions of 44-to 60-week-old ApoE2/2 mice ( Figure 5D ), identifying that SMCs were the major contributors to osteochondrogenic differentiation of ApoE2/2 vessels. Finally, the contribution of SMCs to chondrocyte-like cells of ApoE2/2 vessels was quantified with a similar approach used for LDLr2/2 vessels, and the majority of the Col II-positive cells (95.5%) had once possessed SMC features (see Supplementary material online, Figure S2B ).
Contribution of BM-derived cells to vascular cartilaginous metaplasia and calcification
To determine whether BM-derived cells contribute to the development of cartilaginous metaplasia and calcification in atherosclerotic blood vessels, we assessed aortic arch specimens available from the control group of a previous study. 18 In this study, GFP-expressing BM cells were engrafted into 35-week-old ApoE2/2 mice that were studied 10-week post-transplantation. ApoE2/2 mice of 35 weeks old had only a few foam cells in their aortic arches (negative for Runx2/Cbfa1), suggesting that BM-derived cells that showed osteochondrogenic properties in aortic arches at later time points had entered the vessel wall primarily after 35 weeks of age. By 45 weeks of age, these mice developed cartilaginous metaplasia and calcification similar to LDLr2/2 mice fed with HFD for 24-28 weeks. As shown in Supplementary material online, Figure S3 , 45-week-old ApoE2/2 mice developed not only atherosclerosis (see Supplementary material online, Figure S3A and D) but also cartilaginous metaplasia and calcification (see Supplementary material online, Figure S3B , C, E, and F ) in aortic arches. In smaller lesions, foam cells and lipid-filled areas were distinct from areas of cartilaginous Aortic arches were collected for the study 10 weeks after transplantation. Adjacent sections were stained immunohistochemically for GFP (A -C, brown) and Runx2/Cbfa1 (E and F, brown). (D). Quantitative analysis of GFP-positive osteochondrogenic precursor-like cells in atherosclerotic ApoE2/2 vessels. Inset in C and F. Higher-powered magnification of the boxed region shows colocalization of GFP (brown, arrows) with osteochondrogenic marker Runx2/Cbfa1 (brown, arrows). L, lumen; I, intima; M, media; Ad, adventitia.
metaplasia and calcification. BM-derived GFP-positive cells were mostly found in lesion shoulders (data not shown), lipid cores, and areas filled with foam cells ( Figure 6A and B, brown, vs. Supplementary material online, Figures S3D and E) , accounting for 87% of GFP-positive cells observed in the vessel wall. Significantly, 13% of GFP-positive cells were also positive for Runx2/Cbfa1, residing mostly on the surface of lesions ( Figure 6E vs. B; see Supplementary material online, Figure S4 , arrowheads) with only a few at the sites of cartilaginous metaplasia and calcification ( Figure 6F vs. C, arrows) . These GFP-positive osteochondrogenic cells accounted for 20.1% of total Runx2/Cbfa1-positive cells found in ApoE2/2 vessels ( Figure 6D ), suggesting that BM-derived cells also make a significant contribution to the osteochondrogenic differentiation of atherosclerotic vessels.
Discussion
In the present study, we used a genetic fate mapping strategy to identify sources of cells that give rise to osteochondrogenic precursorand chondrocyte-like cells in atherosclerotic vessels. We introduced to atherosclerotic LDLr2/2 mice a 22. BM-derived vascular progenitors are generally accepted as cells that have the ability to differentiate into vascular SMCs, consequently participating in pathogenesis of atherosclerosis and blood vessel repair. 22 However, this concept has been challenged in recent studies from different laboratories using various lineage tracing strategies. 24 -26 In a model of post-angioplasty restenosis, a time-course analysis of BM-derived progenitors that differentiate into SMCs during neointima formation was performed. GFP-positive BM cells were found to only account for 2% of neointimal SMCs. Most of the GFP-positive BM cells were monocytes/macrophages occurring in the acute inflammatory response, accounting for 69% of the neointimal cells. 25 In a transplant atherosclerosis model, engraftment of SM-LacZ b-galactosidase-expressing marrow cells into aortic allograft recipients revealed that neointimal and atherosclerotic lesions were negative for b-galactosidase staining. 26 Finally, in a hyperlipidaemiaassociated atherosclerotic model, sex-mismatched eGFP+ApoE2/2 marrow cells were engrafted into ApoE2/2 recipients. eGFPpositive cells were mostly seen in lipid-laden areas, co-localizing with macrophage foam cells, identical to our observations. In that study, no eGFP expression was found in 10 000 SMa-actin-positive cells, counted in 154 sections from multiple sites in arteries of 23 BM-transplanted mice. 24 These authors also transplanted ApoE2/2 arterial segments into carotids of eGFP+ApoE2/2 mice and showed no significant eGFP-positive SMCs in lesions of the engrafted vessels. 24 In contrast to the above strategies, we tracked cells of SM origin to determine whether vascular SMCs contribute to cartilaginous and bony elements seen in atherosclerotic vessels. We found that SMCs were mostly located in the fibrous cap of atheromas and areas of cartilaginous metaplasia and calcification. These cells have lost SMC marker protein expression (e.g. SM22a), with the rare exception of some cells on the lumen side of the fibrous cap. In both LDLr2/2 and ApoE2/2 vessels, cells exhibiting chondrocytic properties were largely derived from SMCs as identified by transgene b-galactosidase activity, localizing in the deep intima and inner medial layers near areas of elastic lamina breakage that signifies their likelihood of being derived from vascular medial SMCs. These findings are consistent with our previous observations in MGP2/2 vessels, a model of solely arterial medial calcification, where all the chondrocytes were found to be derived from vascular SMCs. 19 However, the sources of osteochondrogenic precursors that apparently give rise to chondrocytes in atherosclerotic lesions appear to be distinct from those observed in arterial medial calcification of MGP2/2 mice. In atherosclerotic vessels, circulating BM-derived cells were shown to contribute to 20% of the Runx2/Cbfa1-positive osteochondrogenic precursors, whereas no BM-derived cells were found to participate in medial calcification of MGP2/2 vessels. 19 Our finding indicating BM cells as additional sources of osteochondrogenesis seen in atherosclerotic vessels is complemented by a recent study that used SM MHC-Cre recombinase and Cre reporter transgenes to trace BM-derived cells that had once developed SMC property, 27 even though the study is limited by the restricted expression of SM MHC and a fairly low recombination efficiency of SM MHC-Cre. 13 BM-derived cells may have gained SMC properties 22 while differentiating towards osteochondrogenic precursors and chondrocytes after recruitment into the diseased vasculature. Although we did not see a co-localization of macrophages (MOMA-2-positive) with chondrocyte-like cells (Sox9-positive) in atherosclerotic vessels of the animals examined, our studies do not exclude the contribution of monocytes/macrophages to chondrocyte-like cells. It is possible that these cells have lost their phenotype in the diseased blood vessels and are therefore undetectable by lineage-specific antibodies. BM-derived myeloid CD34+ CD13+ cells were recently reported to be the major sources of atherosclerotic intimal chondrocyte-like cells by Doehring et al. 28 In that study, b-galactosidase-positive BM cells were transplanted into LDLr2/2 mice fed with a high-fat diet containing 1.25% cholesterol and 0.5% sodium cholate. BM-derived b-galactosidase-positive cells were found to constitute 7-14% of the total plaque cellularity. Unlike our lineage studies of LDLr2/2 and ApoE2/2 mice, these vessels developed larger necrotic cores, and chondrocyte-like cells (recognized by Col II antibody) were mostly found in the fibrous cap where SMCs are typically found. In addition, 89% of the chondrocytes were found to be derived from BM, as marked by myeloid markers, CD34 and CD13. 28 It is unclear whether these cells had once developed SMC properties due to the phenotypic plasticity of vascular SMCs in calcified lesions. Although LDLr2/2 mice and high-fat diet were used in both studies, sodium cholate was only added to the diet used in Doehring's study. HFDs containing cholate are known to induce hepatic fibrosis resulting from enhanced macrophage infiltration to an inflammatory response, 29 a likely cause of enhanced recruitment of BM myeloid cells and acceleration of lipid-laden and necrotic core formation in Doehring's study. Indeed, in our studies utilizing a GFP transgene to trace cells derived from BM in ApoE2/2 mice, GFP-positive marrow cells were mostly seen in macrophages and foam cells, identifying their major role in inflammation and lipid laden of atherosclerotic lesions. 22, 24, 25 Interestingly, these cells also contributed significantly ( 20%) to osteochondrogenic precursorlike cells found in cartilaginous and calcifying areas of atherosclerotic vessels. Transplantation of GFP marrow cells to ApoE2/2 recipients in our study did not reveal any contribution of BM-derived cells prior to 35 weeks of age. Although only a few foam cells were visualized by this time, it is true that our finding showing 20% contribution of BM-derived cells represents only the marrow cells that have entered the blood vessels within 35-45 weeks of age. Considering the findings of our lineage studies of atherosclerotic LDLr2/2 and ApoE2/2 mice that essentially all chondrocyte-like cells (marked by Sox9 and Col II) were labelled with SMC-specific transgene b-galactosidase, the BM-derived osteochondrogenic cells were likely to have had gained partial SMC characteristics (such as SM22a expression) while differentiating into chondrocytes. Understanding this pathway holds promise for the development of novel therapeutic strategies that control the recruitment and accumulation of BM-derived cells in cartilaginous and bony elements of atherosclerotic vessels.
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